This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In an ideal world, clinicians would decide on the relative merits of treatments based on high-quality evidence from randomized, double-blind, controlled clinical trials. The need for such evidence is particularly acute when there are several treatments available but no trials comparing efficacy. In this issue of Neurology, two randomized clinical trials report the relative benefits of different strategies of MS treatment with parenteral interferons. Although both interferon β-1a and interferon β-1b have been shown to delay the progression of disability in relapsing-remitting MS, there remains uncertainty about the relative benefits of the products available, as well as the optimal dosage, route, and frequency of administration of those products.
The study by Clanet et al.1 was a randomized, double-blind, parallel group trial of two dosages of interferon β-1a. The participants were followed for a minimum of 3 years and the primary outcome variable was the time from randomization until a sustained increase of 1 or more points on …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
